Related Experiment Videos
Dedifferentiated chondrosarcoma--a fatal disease.
1Department of Orthopaedic Surgery, University Hospital, University of Hamburg, Martinistrasse 52, 20246, Hamburg, Germany. j.bruns@uke.uni-hamburg.de
Journal of Cancer Research and Clinical Oncology
|March 24, 2005
Summary
Dedifferentiated chondrosarcoma (DDCS) is a rare bone cancer with a poor prognosis. Surgical resection is crucial, but its impact on long-term outcomes and the role of chemotherapy require further investigation.
Area of Science:
- Orthopedic Oncology
- Skeletal Tumors
- Bone Cancer Research
Background:
- Study focuses on 13 patients diagnosed with dedifferentiated chondrosarcoma (DDCS).
- Mean age at diagnosis was 59.8 years, with most patients staged as IIB or III.
Purpose of the Study:
- To analyze treatment outcomes and prognosis for patients with dedifferentiated chondrosarcoma.
- To evaluate the effectiveness of surgical interventions and adjuvant therapies.
Main Methods:
- Surgical interventions included limb salvage with megaprosthesis, amputation, and pelvic reconstruction.
- Surgical margins (wide, marginal, intralesional) and adjuvant chemotherapy were assessed.
- Data collected on recurrence, survival rates, and metastasis.
Main Results:
- Recurrence occurred in 5/11 surgically treated patients, with higher rates after marginal or intralesional resections.
- No recurrence was observed in 5/11 patients, particularly those with wide resections.
- High mortality rate (11/13 patients dead of disease) and short mean survival (9.7 months) were noted.
Conclusions:
- Dedifferentiated chondrosarcoma (DDCS) is a rare bone tumor with a poor prognosis.
- Surgery is the primary treatment, but the benefit of radical resection on long-term survival is uncertain.
- Limited data exists on neoadjuvant/adjuvant chemotherapy efficacy in DDCS.